2024
Ten Year Follow-up After Face Transplantation – a Single Center Retrospective Cohort Study
Huelsboemer L, Kauke-Navarro M, Boroumand S, Parikh N, Hosseini H, Yu C, Stögner V, Ko C, Perry B, Formica R, Hung P, Mahajan A, Azzi J, Murphy G, Pomahac B. Ten Year Follow-up After Face Transplantation – a Single Center Retrospective Cohort Study. American Journal Of Transplantation 2024 PMID: 39413877, DOI: 10.1016/j.ajt.2024.10.007.Peer-Reviewed Original ResearchChronic rejectionFace transplantationFollow-upSingle center retrospective cohort studyFunctional outcomesSensory returnAnalysis of functional outcomesMedian follow-upIncidence of malignancyMetabolic side effectsGraft rejection episodesComputed tomography angiogramRetrospective cohort studyEvidence of vasculopathyFollow-up periodLong-term outcomesYear follow-upFacial motor functionRejection episodesInfectious complicationsTransplant recipientsPatient ageGraft retentionMedical complicationsCohort studyImmune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions
Knoedler L, Dean J, Diatta F, Thompson N, Knoedler S, Rhys R, Sherwani K, Ettl T, Mayer S, Falkner F, Kilian K, Panayi A, Iske J, Safi A, Tullius S, Haykal S, Pomahac B, Kauke-Navarro M. Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions. Frontiers In Immunology 2024, 15: 1372862. PMID: 38650942, PMCID: PMC11033354, DOI: 10.3389/fimmu.2024.1372862.Peer-Reviewed Original ResearchConceptsRegulatory myeloid cellsSolid organ transplantationVascularized composite allotransplantationMesenchymal stromal cellsT cellsTransplant patientsCellular therapyChimeric antigen receptor T cellsTransplant surgerySide effectsIncreased risk of malignancyProgression to chronic rejectionAcute rejection ratesPerioperative treatment strategiesRegulatory T cellsPromote immune toleranceRisk of malignancySystemic side effectsRelated side effectsCell typesImprove transplant survivalCAR-TCell therapy applicationsImmunosuppressive regimensChronic rejection
2023
Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation
Kauke-Navarro M, Noel O, Knoedler L, Knoedler S, Panayi A, Stoegner V, Huelsboemer L, Pomahac B. Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation. Journal Of Surgical Research 2023, 291: 176-186. PMID: 37429217, DOI: 10.1016/j.jss.2023.04.028.Peer-Reviewed Original ResearchConceptsImmunosuppressive regimensAllograft rejectionComposite allotransplantationDonor-derived immune cellsDonor-derived T lymphocytesRecipient-derived T cellsPotent immunosuppressive regimensToxic immunosuppressive regimensSolid organ transplantationAntigen-presenting cellsSystemic side effectsVascularized Composite AllotransplantationCD40 knockoutChronic rejectionRejection episodesSystemic immunosuppressionMost patientsImmunomodulatory strategiesTolerance inductionImmune cellsOrgan transplantationT cellsT lymphocytesSide effectsClinical successInsights from immunoproteomic profiling of a rejected full-face transplant
Lee C, Wang D, Kauke-Navarro M, Russell-Goldman E, Xu S, Mucciarone K, Sohrabi S, Lian C, Pomahac B, Murphy G. Insights from immunoproteomic profiling of a rejected full-face transplant. American Journal Of Transplantation 2023, 23: 1058-1061. PMID: 37037378, DOI: 10.1016/j.ajt.2023.04.008.Peer-Reviewed Original ResearchConceptsVascularized Composite AllograftsT cellsChronic rejectionCD8-positive T cellsEffector T cellsFull face transplantArteriosclerotic alterationsIntragraft arteriesVCA rejectionGraft arteryAccelerated arteriosclerosisRecipient originPunch biopsyAtherogenic responseComposite allograftsImmunoproteomic profilingDioxygenase 1Target endotheliumArteryEndotheliumProteomic profilingPathway componentsCellsRejectionAllograftsTolerance Induction in Vascularized Composite Allotransplantation—A Brief Review of Preclinical Models
Huelsboemer L, Kauke-Navarro M, Reuter S, Stoegner V, Feldmann J, Hirsch T, Kueckelhaus M, Dermietzel A. Tolerance Induction in Vascularized Composite Allotransplantation—A Brief Review of Preclinical Models. Transplant International 2023, 36: 10955. PMID: 36846605, PMCID: PMC9946984, DOI: 10.3389/ti.2023.10955.Peer-Reviewed Original ResearchConceptsTolerance inductionLong-term effectsAnimal modelsImmune systemDonor-specific toleranceLong-term outcomesRecipient's immune systemPreclinical animal modelsNovel therapeutic strategiesPre-clinical studiesVascularized Composite AllotransplantationChronic rejectionImmunosuppressive protocolsTransplant recipientsAllograft rejectionOrgan dysfunctionPreclinical modelsComposite allograftsTherapeutic strategiesComposite allotransplantationClinical practiceIS protocolClinical translationInductionReview article
2021
Long-term Outcomes After Facial Allotransplantation: Systematic Review of the Literature
Tchiloemba B, Kauke M, Haug V, Abdulrazzak O, Safi AF, Kollar B, Pomahac B. Long-term Outcomes After Facial Allotransplantation: Systematic Review of the Literature. Transplantation 2021, 105: 1869-1880. PMID: 33148976, DOI: 10.1097/tp.0000000000003513.Peer-Reviewed Original ResearchConceptsSystematic reviewAcute cell-mediated rejectionPositive risk-benefit ratioRecurrent acute rejection episodesLong-term outcome dataAcute rejection episodesChronic vascular rejectionFirst year posttransplantImmunosuppression-related complicationsCell-mediated rejectionSingle-center experiencePubMed/MEDLINE databaseLong-term outcomesRisk-benefit ratioEnglish full-text articlesQuality of lifeFull-text articlesAcute rejectionAllograft lossChronic rejectionRejection episodesVascular rejectionInfectious complicationsInfectious episodesMetabolic complications